Forefront Analytics LLC Raises Stock Holdings in Immatics (NASDAQ:IMTX)

Forefront Analytics LLC increased its stake in shares of Immatics (NASDAQ:IMTX) by 42.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,911 shares of the company’s stock after purchasing an additional 4,731 shares during the quarter. Forefront Analytics LLC’s holdings in Immatics were worth $113,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. DAFNA Capital Management LLC raised its position in shares of Immatics by 69.0% in the fourth quarter. DAFNA Capital Management LLC now owns 245,000 shares of the company’s stock valued at $1,742,000 after buying an additional 100,000 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Immatics by 686.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 278,382 shares of the company’s stock worth $1,979,000 after purchasing an additional 242,988 shares during the period. Braidwell LP lifted its stake in shares of Immatics by 112.7% during the 4th quarter. Braidwell LP now owns 3,503,965 shares of the company’s stock worth $24,913,000 after purchasing an additional 1,856,400 shares during the period. Baker BROS. Advisors LP boosted its holdings in shares of Immatics by 12.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,275,830 shares of the company’s stock worth $51,731,000 after purchasing an additional 832,432 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares during the period. Institutional investors and hedge funds own 64.41% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a research note on Tuesday, April 1st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $16.67.

Immatics Stock Down 2.3 %

IMTX stock opened at $4.24 on Friday. The company has a market cap of $515.37 million, a price-to-earnings ratio of -6.42 and a beta of 0.87. The business has a fifty day simple moving average of $4.48 and a 200-day simple moving average of $6.03. Immatics has a 52 week low of $3.30 and a 52 week high of $13.77.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.51. The company had revenue of $15.67 million during the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. As a group, analysts expect that Immatics will post -0.72 earnings per share for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.